Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome

Last updated: February 18, 2025
Sponsor: Carelon Research
Overall Status: Completed

Phase

3

Condition

Connective Tissue Diseases

Severe Short Stature

Treatment

Losartan Potassium

Atenolol

Clinical Study ID

NCT00429364
461
U01HL068270
  • Ages 6-25
  • All Genders

Study Summary

Marfan syndrome is a hereditary connective tissue disorder. Many individuals with this condition die because of the associated heart and blood vessel abnormalities. This study will compare the effectiveness of two medications, losartan and atenolol, at slowing aortic root enlargement in individuals with Marfan syndrome.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of Marfan syndrome, according to Ghent criteria (more information can befound in Appendix D of the protocol)

  • Aortic root Z-score greater than 3.0

Exclusion

Exclusion Criteria:

  • Prior aortic surgery

  • Aortic root dimension at the sinuses of Valsalva greater than 5 cm

  • Planned aortic surgery within 6 months of study entry

  • Aortic dissection

  • Shprintzen-Goldberg syndrome

  • Loeys-Dietz syndrome

  • Therapeutic (i.e., for arrhythmia, ventricular dysfunction, or valve regurgitation)rather than prophylactic use of angiotensin-converting enzyme (ACE) inhibitor,beta-blocker, or calcium channel blocker

  • History of angioedema while taking an ACE inhibitor or beta-blocker

  • Intolerance to losartan or other angiotensin II receptor blocker (ARB) that resultedin termination of therapy

  • Intolerance to atenolol or other beta-blocker that resulted in termination oftherapy

  • Kidney dysfunction (i.e., creatinine greater than the upper limit of age-relatednormal values)

  • Asthma of sufficient severity to prohibit the use of a beta-blocker

  • Chronic use of steroids and/or beta-adrenergic agents with exacerbations of asthmathat are frequent (averaging three or more per year) or severe (requiringhospitalization)

  • Diabetes mellitus

  • Pregnant or planning to become pregnant within 36 months of study entry

  • Inability to complete study procedures, including history of poor acoustic windows (i.e., inability to obtain accurate measurement of aortic root)

Study Design

Total Participants: 608
Treatment Group(s): 2
Primary Treatment: Losartan Potassium
Phase: 3
Study Start date:
January 01, 2007
Estimated Completion Date:
February 28, 2014

Study Description

Marfan syndrome is an inheritable disorder that affects the body's connective tissue. An abnormal protein results in connective tissue that is weaker than normal. Because connective tissue is found throughout the body, Marfan syndrome can affect many body systems, including the skeleton, eyes, nervous system, skin, lungs, heart, and blood vessels. Overall, heart and blood vessel abnormalities are the leading cause of death in individuals with Marfan syndrome. A common blood vessel abnormality associated with this disease involves the aorta, which is the large artery that carries blood away from the heart to the rest of the body. The aortic root, the portion of the aorta that is attached to the heart, may enlarge and tear or even rupture. A tear or rupture is considered a life-threatening emergency. Recent studies have shown that the medication losartan may reduce aortic root growth and improve heart function. The purpose of this study is to compare the effectiveness of losartan versus atenolol at slowing aortic root growth in individuals with Marfan syndrome.

This 3-year study will enroll individuals with Marfan syndrome. Participants will be randomly assigned to receive either losartan or atenolol on a daily basis. All participants will initially receive a low dose of their assigned medication. This dose will be gradually increased every 3 to 4 weeks until the maximum tolerated dose is reached. A continuous electrocardiogram (ECG) that monitors heart rate and activity in 24-hour intervals will be used to determine the proper dose increase for each participant. Participants will then receive the maximum tolerated dose for the remainder of the study. Study visits will occur at baseline and Months 6, 12, 24, and 36. Each study visit will include a physical examination, a medical history review, an ECG, an echocardiogram, and questionnaires. Additionally, at the baseline study visit blood will be collected for laboratory testing.

Connect with a study center

  • Ghent University Hospital

    De Pintelaan, Gent 185 9000
    Belgium

    Site Not Available

  • Ghent University Hospital

    Ghent, Gent 185 9000
    Belgium

    Site Not Available

  • Hospital for Sick Children

    Toronto, Ontario M5G 1X8
    Canada

    Site Not Available

  • Cedars-Sinai Medical Center

    Los Angeles, California 90048
    United States

    Site Not Available

  • Lucile Packard Children's Hospital

    Palo Alto, California 94304
    United States

    Site Not Available

  • Rady Children's Hospital / UCSD

    San Diego, California 92123
    United States

    Site Not Available

  • Stanford University School of Medicine

    Stanford, California 94305
    United States

    Site Not Available

  • Children's Memorial Hospital

    Chicago, Illinois 60614
    United States

    Site Not Available

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland 21205
    United States

    Site Not Available

  • Children's Hospital Boston

    Boston, Massachusetts 02115
    United States

    Site Not Available

  • Children's Hospital of Minnesota - St. Paul

    Saint Paul, Minnesota 55102
    United States

    Site Not Available

  • Children's Hospital of Minnesota - St. Paul

    St. Paul, Minnesota 55102
    United States

    Site Not Available

  • Washington University School of Medicine

    Saint Louis, Missouri 63110
    United States

    Site Not Available

  • Washington University School of Medicine

    St Louis, Missouri 63110
    United States

    Site Not Available

  • Columbia College of Physicians and Surgeons

    New York, New York 10032
    United States

    Site Not Available

  • Mount Sinai Medical Center

    New York, New York 10029
    United States

    Site Not Available

  • Weill Medical College of Cornell University

    New York, New York 10021
    United States

    Site Not Available

  • Duke University Medical Center

    Durham, North Carolina 27710
    United States

    Site Not Available

  • Brody School of Medicine at East Carolina University

    Greenville, North Carolina 27834
    United States

    Site Not Available

  • Wake Forest University Baptist Medical Center

    Winston-Salem, North Carolina 27157
    United States

    Site Not Available

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio 45229
    United States

    Site Not Available

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania 19104
    United States

    Site Not Available

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania 19104
    United States

    Site Not Available

  • Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania 15213
    United States

    Site Not Available

  • Medical University of South Carolina

    Charleston, South Carolina 29425
    United States

    Site Not Available

  • Vanderbilt University Medical Center

    Nashville, Tennessee 37212
    United States

    Site Not Available

  • Texas Children's Hospital

    Houston, Texas 77030
    United States

    Site Not Available

  • Primary Children's Medical Center

    Salt Lake City, Utah 84113
    United States

    Site Not Available

  • Seattle Children's Hospital

    Seattle, Washington 98105
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.